Guangzhou Innogen Pharmaceutical Technology

Guangzhou Innogen Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative therapies for metabolic diseases. The company's primary focus is on the research and development of treatments for type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Innogen's lead candidate is a long-acting GLP-1 receptor agonist, currently in late-stage clinical trials, designed to provide superior glycemic control and weight loss benefits. By leveraging its expertise in peptide and small molecule drug discovery, Innogen aims to address significant unmet medical needs in the global metabolic health market.